Peter Mombaerts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Mombaerts has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
Mona Khan
Max Planck Research Unit for Neurogenetics, Frankfurt, Germany
12 shared publications- Bolek Zapiec
Max Planck Research Unit for Neurogenetics, Max-von-Laue-Strasse 4, 60438 Frankfurt, Germany
5 shared publications Bolek Zapiec
Max Planck Research Unit for Neurogenetics Frankfurt Germany
3 shared publicationsJiangwei Lin
Max Planck Research Unit for Neurogenetics, Frankfurt, Germany
3 shared publications- Joost Wauters
Medical Intensive Care Unit University Hospitals Leuven Leuven Belgium
3 shared publications Mark Jorissen
Department of Neurosciences, Experimental Otorhinolaryngology, Rhinology Research, KU Leuven, Leuven, Belgium; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium
3 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 62 (11) , e70327
Glomeruli of the Mouse Olfactory Bulb: Numbers, Sizes, Shapes
The discovery of olfactory bulb glomeruli was reported by the neuroanatomist Camillo Golgi in 1875, but the number of glomeruli in a mammalian olfactory bulb remains unknown. The 1141 intact odorant receptor genes in the mouse genome are key determinants of the coalescence of axons of olfactory sensory neurons into glomeruli at recognizable positions in the olfactory bulb. Here, we devised a methodology for quantifying the numbers, sizes, and shapes of the glomeruli of mouse olfactory bulbs. Using serial two‐photon tomography, we generated complete image stacks of 12 mouse olfactory bulbs labeled immunohistochemically as whole mounts with antibodies against the glomerular marker VGLUT2. The mouse ages were postnatal days 14, 21, and 56. We manually segmented 33,137 glomeruli based on the VGLUT2‐immunoreactive signal. This manual segmentation resulted in complete empirical counts of the heterogeneously‐sized glomerular 3D objects instead of providing only statistical estimates. We counted a median of 2851 glomeruli per olfactory bulb at postnatal day 56, corresponding to 2.50 glomeruli per intact odorant receptor gene per olfactory bulb. For a 3D object of any shape, the effective diameter is defined as the diameter of a sphere that possesses the equivalent volume. We found that the effective diameters of the glomeruli are well modeled by a Gaussian distribution, with a median of 77.54 μm at postnatal day 56. By quantifying glomerular shape with aspect‐length ratios and sphericity, we demonstrate that glomeruli do not conform to spherical shapes. We propose the descriptor “tuberiform” to encompass the diversity of glomerular shapes.
- 8 December 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 62 (11) , e70327
Open AccessGlomeruli of the Mouse Olfactory Bulb: Numbers, Sizes, Shapes
The discovery of olfactory bulb glomeruli was reported by the neuroanatomist Camillo Golgi in 1875, but the number of glomeruli in a mammalian olfactory bulb remains unknown. The 1141 intact odorant receptor genes in the mouse genome are key determinants of the coalescence of axons of olfactory sensory neurons into glomeruli at recognizable positions in the olfactory bulb. Here, we devised a methodology for quantifying the numbers, sizes, and shapes of the glomeruli of mouse olfactory bulbs. Using serial two‐photon tomography, we generated complete image stacks of 12 mouse olfactory bulbs labeled immunohistochemically as whole mounts with antibodies against the glomerular marker VGLUT2. The mouse ages were postnatal days 14, 21, and 56. We manually segmented 33,137 glomeruli based on the VGLUT2‐immunoreactive signal. This manual segmentation resulted in complete empirical counts of the heterogeneously‐sized glomerular 3D objects instead of providing only statistical estimates. We counted a median of 2851 glomeruli per olfactory bulb at postnatal day 56, corresponding to 2.50 glomeruli per intact odorant receptor gene per olfactory bulb. For a 3D object of any shape, the effective diameter is defined as the diameter of a sphere that possesses the equivalent volume. We found that the effective diameters of the glomeruli are well modeled by a Gaussian distribution, with a median of 77.54 μm at postnatal day 56. By quantifying glomerular shape with aspect‐length ratios and sphericity, we demonstrate that glomeruli do not conform to spherical shapes. We propose the descriptor “tuberiform” to encompass the diversity of glomerular shapes.
- 3 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (827) , eadw9578
Anakinra restores immunological misfiring that drives influenza-associated pulmonary aspergillosis
Influenza-associated pulmonary aspergillosis (IAPA) is a severe fungal superinfection affecting critically ill patients with influenza. Current treatments target the causative pathogens but do not address the dysregulated host immune responses that drive morbidity. Host-directed immunotherapies could overcome this treatment gap. Here, we studied the host-pathogen factors driving IAPA using patient samples and an IAPA mouse model. We identified interleukin-1 (IL-1)–mediated inflammation, neutrophil activation, and neutrophil extracellular trap (NET) release as crucial features in IAPA pathogenesis. This inflammation led to an immunological imbalance with defective neutrophil effector functions, including impaired reactive oxygen production (ROS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, thereby impairing the fungal host immune response toward a permissive environment for Aspergillus fumigatus . Blocking the IL-1 receptor with anakinra reduced inflammation and NET release, restored ROS production in neutrophils, and rescued influenza virus–infected mice from invasive pulmonary aspergillosis. Our findings underscore the crucial role of IL-1–driven inflammation in the immunological misfiring that drives IAPA and suggest anakinra as a promising immunomodulatory therapy for patients with IAPA.
- 3 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (827) , eadw9578
Anakinra restores immunological misfiring that drives influenza-associated pulmonary aspergillosis
Influenza-associated pulmonary aspergillosis (IAPA) is a severe fungal superinfection affecting critically ill patients with influenza. Current treatments target the causative pathogens but do not address the dysregulated host immune responses that drive morbidity. Host-directed immunotherapies could overcome this treatment gap. Here, we studied the host-pathogen factors driving IAPA using patient samples and an IAPA mouse model. We identified interleukin-1 (IL-1)–mediated inflammation, neutrophil activation, and neutrophil extracellular trap (NET) release as crucial features in IAPA pathogenesis. This inflammation led to an immunological imbalance with defective neutrophil effector functions, including impaired reactive oxygen production (ROS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, thereby impairing the fungal host immune response toward a permissive environment for Aspergillus fumigatus . Blocking the IL-1 receptor with anakinra reduced inflammation and NET release, restored ROS production in neutrophils, and rescued influenza virus–infected mice from invasive pulmonary aspergillosis. Our findings underscore the crucial role of IL-1–driven inflammation in the immunological misfiring that drives IAPA and suggest anakinra as a promising immunomodulatory therapy for patients with IAPA.
- Open Access
In vivo and contrast-enhanced ex vivo micro-computed tomography for anatomical imaging of Octodon degus
- Open Access
- 8 November 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-19
Visualizing the human olfactory projection and ancillary structures in a 3D reconstruction
Visualizing in 3D the histological microanatomy of the human olfactory projection from the olfactory mucosa in the nasal cavity to the olfactory bulbs in the cranial cavity necessitates a workflow for handling a great many sections. Here, we assembled a 3D reconstruction of a 7.45 cm3en-bloc specimen extracted from an embalmed human cadaver. A series of 10 µm coronal sections was stained with quadruple fluorescence histology and scanned in four channels. A trained anatomist manually segmented six structures of interest in a subset of the sections to generate the ground truth. Six convolutional neural networks were then trained for automatic segmentation of these structures in 1234 sections. A high-performance computing solution was engineered to register the sections based on the fluorescence signal and segmented structures. The resulting 3D visualization offers several novel didactic opportunities of interactive exploration and virtual manipulation. By extrapolating manual counts of OSNs in a subset of sections to the calculated volume of the envelope of the entire olfactory epithelium, we computed a total of ~2.7 million OSNs in the specimen. Such empirically derived information helps assess the extent to which the organizational principles of the human olfactory projection may differ from those in mice.
- 8 November 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-19
Open AccessVisualizing the human olfactory projection and ancillary structures in a 3D reconstruction
Visualizing in 3D the histological microanatomy of the human olfactory projection from the olfactory mucosa in the nasal cavity to the olfactory bulbs in the cranial cavity necessitates a workflow for handling a great many sections. Here, we assembled a 3D reconstruction of a 7.45 cm3en-bloc specimen extracted from an embalmed human cadaver. A series of 10 µm coronal sections was stained with quadruple fluorescence histology and scanned in four channels. A trained anatomist manually segmented six structures of interest in a subset of the sections to generate the ground truth. Six convolutional neural networks were then trained for automatic segmentation of these structures in 1234 sections. A high-performance computing solution was engineered to register the sections based on the fluorescence signal and segmented structures. The resulting 3D visualization offers several novel didactic opportunities of interactive exploration and virtual manipulation. By extrapolating manual counts of OSNs in a subset of sections to the calculated volume of the envelope of the entire olfactory epithelium, we computed a total of ~2.7 million OSNs in the specimen. Such empirically derived information helps assess the extent to which the organizational principles of the human olfactory projection may differ from those in mice.
- Open Access
- 5 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology
Human parainfluenza virus type 3 (HPIV-3) can cause severe respiratory tract infections. There are no convenient small-animal infection models. Here, we show viral replication in the upper and lower airways of AG129 mice (double IFNα/β and IFNγ receptor knockout mice) upon intranasal inoculation. By multiplex fluorescence RNAscope and immunohistochemistry followed by confocal microscopy, we demonstrate viral tropism to ciliated cells and club cells of the bronchiolar epithelium. HPIV-3 causes a marked lung pathology. No virus transmission of the virus was observed by cohousing HPIV-3-infected AG129 mice with other mice. Oral treatment with GS-441524, the parent nucleoside of remdesivir, reduced infectious virus titers in the lung, with a relatively normal histology. Intranasal treatment also affords an antiviral effect. Thus, AG129 mice serve as a robust preclinical model for developing therapeutic and prophylactic strategies against HPIV-3. We suggest further investigation of GS-441524 and its prodrug forms to treat HPIV-3 infection in humans.
- 5 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Open AccessA robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology
Human parainfluenza virus type 3 (HPIV-3) can cause severe respiratory tract infections. There are no convenient small-animal infection models. Here, we show viral replication in the upper and lower airways of AG129 mice (double IFNα/β and IFNγ receptor knockout mice) upon intranasal inoculation. By multiplex fluorescence RNAscope and immunohistochemistry followed by confocal microscopy, we demonstrate viral tropism to ciliated cells and club cells of the bronchiolar epithelium. HPIV-3 causes a marked lung pathology. No virus transmission of the virus was observed by cohousing HPIV-3-infected AG129 mice with other mice. Oral treatment with GS-441524, the parent nucleoside of remdesivir, reduced infectious virus titers in the lung, with a relatively normal histology. Intranasal treatment also affords an antiviral effect. Thus, AG129 mice serve as a robust preclinical model for developing therapeutic and prophylactic strategies against HPIV-3. We suggest further investigation of GS-441524 and its prodrug forms to treat HPIV-3 infection in humans.
- Open Access
- 22 May 2023
- Published by Elsevier in EBioMedicine
- Vol. 92, 104608
Visualising SARS-CoV-2 infection of the lung in deceased COVID-19 patients
- 22 May 2023
- Published by Elsevier in EBioMedicine
- Vol. 92, 104608
Open AccessVisualising SARS-CoV-2 infection of the lung in deceased COVID-19 patients
- Open Access
- 10 March 2022
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 10 (4) , e603
Lung donation and SARS‐CoV‐2 transmission: Missed detection versus missed opportunity?
Point‐of‐care tests may play a valuable role in reducing the risk of donor‐derived SARS‐CoV‐2 transmission in lung transplantation.
- 10 March 2022
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 10 (4) , e603
Open AccessLung donation and SARS‐CoV‐2 transmission: Missed detection versus missed opportunity?
Point‐of‐care tests may play a valuable role in reducing the risk of donor‐derived SARS‐CoV‐2 transmission in lung transplantation.
- Top Cited PapersOpen Access
Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb